Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics of Ketoconazole Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

NCT00931073
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 18, 2009 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

NCT01454076
View directory record Official record
Conditions
Nonhematologic Malignancies, Lymphoma
Interventions
Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors

NCT00096317
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone, ketoconazole
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study Between Colchicine and Ketoconazole

NCT00983216
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Ketoconazole
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade

NCT00129207
View directory record Official record
Conditions
Tumors
Interventions
bortezomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2008 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet

NCT01240226
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0941, ketoconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics

NCT01318265
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980

NCT01473316
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0980, Ketoconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole

NCT01627587
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
GSK221149 750 mg, Ketoconazole, GSK221149 100 mg, GSK221149 750 mg Fasted, GSK221149 750 mg + Food
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

NCT00404378
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
ketoconazole, casopitant 100 mg, Casopitant 50 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus

NCT00302224
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
2S, 4R Ketoconazole (DIO-902)
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Omaha, Nebraska • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2008 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ketoconazole on the Pharmacokinetics of Refametinib

NCT01925638
View directory record Official record
Conditions
Drug Interactions
Interventions
BAY86-9766, Ketoconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

Ketoconazole Plus Docetaxel to Treat Prostate Cancer

NCT00032825
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Ketaconazole, Docetaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil

NCT00770042
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Ritonavir, Ketoconazole, Erythomycin, Avanafil
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

NCT01969669
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
ABT-199, Ketoconazole
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Tucson, Arizona • Lebanon, New Hampshire • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

NCT00659555
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, Ketoconozole tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects

NCT01657838
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Ketoconazole, Healthy Adult Volunteers
Interventions
Isavuconazole, Ketoconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants

NCT01626651
View directory record Official record
Conditions
Healthy
Interventions
Ibrutinib, Ketoconazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects

NCT01468714
View directory record Official record
Conditions
Human Volunteers
Interventions
PF-04937319 / ketoconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 6, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers

NCT01124760
View directory record Official record
Conditions
Pharmacokinetics
Interventions
AZD9742, Diltiazem, ketoconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 6, 2026, 1:08 PM EDT